D6-04: Increased numbers of endothelial progenitor cells in peripheral blood and tumour specimens in non small cell lung cancer patients. A methodological challenge and ongoing debate on the clinical relevance  by Pircher, Andreas et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS408
D6-04 Molecular Biology & Prognostic Factors, Thu, 12:30 - 14:15
Increased numbers of endothelial progenitor cells in peripheral 
blood and tumour specimens in non small cell lung cancer patients. 
A methodological challenge and ongoing debate on the clinical 
relevance
Pircher, Andreas Skvortsov, Sergej Dlaska, Margit Untergasser, G 
Kaehler, Christian M. Schmid, Thomas Hilbe, Wolfgang 
Medical University Innsbruck, Innsbruck, Austria
Background: Preclinical studies demonstrated that bone marrow 
derived endothelial progenitor cells (EPC) play an important role in 
neovascularisation and tumour growth. However, the clinical relevance 
of EPC on blood vessel formation in NSCLC is unclear. EPC represent 
an immature subset of CD34 positive cells expressing the glykosylated 
polypeptide CD133. Early EPC, which are found in the bone marrow, 
are characterised by their expression of CD34, CD133 and VEGFR2 
(KDR). More mature EPC are found in peripheral blood and are posi-
tive for VEGFR2 and CD34, but have lost CD133. EPC numbers in 
the circulation are very low and therefore their detection is technically 
challenging. In the present study two different immuncytological tech-
niques are presented and compared with each other. In addition, EPC 
numbers were correlated with plasma levels of VEGF, which is known 
to be the major trigger to mobilize EPC. Furthermore, the distribution 
and frequency of CD133 positive EPC in fresh frozen tumour speci-
mens were deﬁned.
Method: 10 NSCLC patients and 5 control patients were analysed in 
the present study. Blood analyses were done before and after surgery. 
EPC were isolated from whole blood by using magnetic beads coupled 
to an antibody directed against CD34 (MACS). After the positive selec-
tion, CD34 MNC were divided into two groups. One group underwent 
FACS analyses labelled with CD34, CD133, VEGFR2, CD45 and 
VE-Cadherin. The other group was assessed by immunocytological 
staining for CD133 (MZA). Cryostat sections were stained for CD133, 
CD31 and Cytokeratin A7. Serum levels of VEGF were quantiﬁed by 
sandwich ELISA.
Results: Compared to the control group, in NSCLC patients, EPC 
counts were signiﬁcantly elevated in peripheral blood before and after 
surgery. The presented alternative method, the MZA assay, correlated 
statistically signiﬁcantly with the standard method, the FACS analysis 
for CD34 VEGFR2 double positive cells. The major advantage of MZA 
was that even singular positive cells were detectable. Taken pre- and 
post-surgery measurements together, a statistically relevant/signiﬁcant 
trend between EPC numbers and VEGF levels was detected. In seven 
of ten tumour samples, increased numbers of CD133 positive cells 
were found and in some cases capillary forming CD133 positive struc-
tures were detectable. All EPC counts measured in the tumour patients 
were statistically signiﬁcantly elevated compared with the healthy 
control group.
Conclusions: A signiﬁcant increase of EPC was detected in patients 
with NSCLC, suggesting an involvement of EPC in tumour vasculo-
genesis and tumour growth in these patients. The MZA method is a 
valuable alternative for the detection of EPC compared to the FACS 
analysis in the peripheral blood, due to its ability to measure even 
singular positive cells. 
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Genomic profile of invasion in lung adenocarcinoma with 
bronchioloalveolar features (AWBF)
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Background: Bronchioloalveolar carcinoma (BAC) is a subtype 
of lung adenocarcinoma (ADC) that by deﬁnition lacks evidence of 
stromal, vascular or pleural invasion. However, the histological criteria 
for diagnosis, their interpretation and the pre-invasive concept of BAC 
remain controversial. We used array comparative genomic hybridiza-
tion (CGH) to compare the genome-wide changes of BAC between no 
or possible micro-invasive samples with invasive AWBF samples to 
identify candidate genetic markers for invasion or poor prognosis. 
Methods: Genomic proﬁles of 14 non- or micro-invasive BAC and 15 
invasive AWBF were obtained using the whole genome submegabase 
resolution tiling set (SMRT) CGH arrays. Candidate marker genes for 
invasion were selected using multiple computational tools. Findings 
were validated in silico, by ﬂuorescent in situ hybridization (FISH) and 
by quantitative polymerase chain reaction (qPCR) using independent 
lung adenocarcinoma samples.
Results: Genomic proﬁles of non- and micro-invasive BAC cannot be 
distinguished, both showing mainly low copy gains on 1p, 2q, 5p, 7p, 
11p, 11q, 12q, 16p, 16q, 17q, 20q and 21q. Most aberrations occurred 
at the sub-telomeric chromosomal regions. AWBF had a similar pattern 
of chromosomal aberrations but with greater variability, frequency and 
range. In addition, deletions were more evident mainly on 3p, 4q, 5q, 
6q and 13q. Synchronous BAC and invasive AWBF from the same 
patient showed increased genomic instability in the latter. Progression 
was also noted between the BAC-like and invasive areas of AWBF. We 
identiﬁed 113 candidate marker genes for tumor invasion and pro-
gression and validated in silico one quarter of them as poor prognotic 
markers in early stage ADC. We further validated the ampliﬁcation 
and overexpression of two genes, PDCD6 and TERT, both located on 
chromosome 5p that showed prominent genomic change. PDCD6 is a 
novel poor prognostic marker for overall survival (HR=4.94, 95% CI 
1.22-8.52, p=0.02) in early stage ADC patients. 
Conclusions: Invasive AWBF can be molecularly distinguished from 
BAC by greater genomic aberrations, which may include markers for 
invasion and poor prognosis for early lung ADC. 
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Detection of circulating tumour cells from peripheral 
blood samples by a novel cell concentration method and 
immunohistochemistry (IHC) compared with reverse 
transcriptase-polymerase chain reaction (RT-PCR) in Stage III/IV 
Non-small cell lung cancer (NSCLC)
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Wan3 Sheehan, Finbarr1 
1 Vancouver Cancer Centre, Vancouver, BC, Canada 2 StemCell Tech-
nologies Inc, Vancouver, BC, Canada 3 B.C. Cancer Research Centre, 
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Background: The prognosis of advanced NSCLC remains poor despite 
aggressive treatment such as concurrent chemoradiotherapy, which can 
